Physician profile
Mathew Luke
NPI 1790772044
$8,623.05
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $465 · 2021: $4,893 · 2022: $554 · 2023: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.09 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,721.67 | 2021 | |
| Glaxosmithkline, LLC. | $1,650.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $661.67 | 2019-2023 | Opdivo, Pomalyst |
| Novartis Pharmaceuticals Corporation | $530.65 | 2019-2021 | |
| Amgen INC. | $510.74 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Seagen INC. | $453.72 | 2020-2023 | Adcetris |
| Janssen Biotech, INC. | $433.16 | 2019-2021 | |
| Eisai INC. | $344.22 | 2019-2020 | |
| Genentech USA, INC. | $334.17 | 2019-2022 | |
| Incyte Corporation | $263.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.63 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $179.74 | 2019-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $177.51 | 2019-2021 | |
| Array Biopharma INC | $156.27 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $152.61 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $145.13 | 2019 | |
| Stemline Therapeutics INC. | $132.57 | 2023 | Orserdu |
| Lilly USA, LLC | $117.87 | 2019-2021 | |
| Pfizer INC. | $113.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $86.44 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $39.40 | 2019 | |
| Boston Scientific Corporation | $37.76 | 2019 | |
| Emd Serono, INC. | $32.10 | 2019 | |
| Rigel Pharmaceuticals, INC. | $30.30 | 2021 | |
| Genzyme Corporation | $22.72 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.64 | 2020 | |
| Astellas Pharma US INC | $18.53 | 2021 | |
| Exelixis INC. | $17.75 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.